# TABLE OF CONTENTS

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Outcomes of the Commission’s 66th Regular Session</td>
</tr>
<tr>
<td>B</td>
<td>Preparations for the 2024 CND High Level Segment</td>
</tr>
<tr>
<td>C</td>
<td>The work of the Commission’s Subsidiary Bodies</td>
</tr>
<tr>
<td>D</td>
<td>CND’s Contribution to the Work of the ECOSOC, including in preparation for the SDG Summit 2023</td>
</tr>
</tbody>
</table>
66TH REGULAR SESSION OF THE CND
13 – 17 MARCH 2023

- 2,500 PARTICIPANTS
- 139 STATES
- 6 UN BODIES AND AGENCIES
- 19 IGOs
- 134 NGOs
- 155 SIDE EVENTS AND 27 EXHIBITIONS
- 4 RESOLUTIONS, 7 DECISIONS
<table>
<thead>
<tr>
<th>Resolution</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>66/1</strong></td>
<td>Preparations for the midterm review to be held during the sixty-seventh session of the Commission on Narcotic Drugs, in 2024</td>
</tr>
<tr>
<td><strong>66/2</strong></td>
<td>Safe handling and disposal of synthetic drugs, their precursors and other chemicals used in the illicit manufacture of drugs</td>
</tr>
<tr>
<td><strong>66/3</strong></td>
<td>Strengthening information sharing to increase scientific evidence-based support to international scheduling and the effective implementation of international scheduling decisions</td>
</tr>
<tr>
<td><strong>66/4</strong></td>
<td>Promoting alternative development as a development-oriented drug control strategy that is sustainable and inclusive</td>
</tr>
</tbody>
</table>
### Scheduling Decisions Adopted at the 66th CND

<table>
<thead>
<tr>
<th>Schedule I of the 1961 Convention</th>
<th>Schedule II of the 1971 Convention</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-methyl-AP-237</td>
<td>ADB-BUTINACA</td>
</tr>
<tr>
<td>etazene</td>
<td><em>alpha</em>-PiHP</td>
</tr>
<tr>
<td>etonitazepyne</td>
<td>3-methylmethcathinone</td>
</tr>
<tr>
<td>protonitazene</td>
<td></td>
</tr>
</tbody>
</table>
ACCELERATION OF THE IMPLEMENTATION of all international drug policy commitments

**2024 MID-TERM REVIEW**

**MARCH 2019**
ADOPITION OF THE MINISTERIAL DECLARATION

**CHAIR’S MODALITIES RESOLUTION 2023:** FORMAT & OUTCOME OF 2024 REVIEW

**2029**
REVIEW PROGRESS IN IMPLEMENTING ALL INTERNATIONAL DRUG POLICIES
At its 66th session, the CND decided on the modalities of the 2024 CND Midterm Review through a Chair’s Modalities Resolution:

To convene a 2-day high-level segment in addition to the 5-day regular session of the CND in 2024, consisting of:

a) General Debate
b) Two multi-stakeholder roundtables on the topics of “Taking stock: work undertaken since 2019” and “The way forward: the road to 2029” - outcome of roundtables: Co-Chair’s summary

To work in good faith towards adopting a concise, action-oriented document at the opening of the high-level segment of its 67th session focused on:

• taking stock of the implementation of all existing international drug policy commitments between 2019 and 2023,
• indicating the work to be done to accelerate the implementation in from 2024 to 2029 of all existing commitments
In the multiyear workplan 2019 – 2023, Member States committed to holding in the period up to 2024, every autumn, interactive meetings that aim to address challenges identified in the ‘stock-taking’ part of the 2019 Ministerial Declaration.

- **June 2019**: Adoption of multiyear workplan 2019 – 2023
- **March 2019**: Adoption of 2019 Ministerial Declaration
- **16 – 18 October 2019**: Thematic Discussions
- **19 – 21 October 2020**: Thematic Discussions
- **19 – 21 October 2021**: Thematic Discussions
- **21 – 22 September 2022**: Thematic Discussions
- **23-25 October & 4-6 December 2023**: Thematic Discussions, with comprehensive stock-taking in 2023
- **2024**: Mid-term review
- **2029**: Review of progress in implementation of all international drug policy commitments
C. REGIONAL CONTRIBUTIONS – CND SUBSIDIARY BODIES

20 to 23 June
HONLEA Europe (Albania)

11 – 15 September*
HONLEA Africa (Nigeria)

2 – 6 October*
HONLEA Latin America (Ecuador)

23 – 27 October*
HONLEA Asia and the Pacific (Indonesia)

21 – 24 November*
Subcommission Meeting (Kyrgyzstan)

Key to **effective implementation** of policy documents

Strengthen the **regular exchange** of information, good practices and lessons learned among practitioners through CND subsidiary bodies

**returned to in-person participation** in 2022

*Dates to be confirmed
D. CONTRIBUTIONS TO THE WORK OF ECOSOC

High-level Political Forum 10-19 July 2023

Theme

Accelerating the recovery from the coronavirus disease (COVID-19) and the full implementation of the 2030 Agenda for Sustainable Development at all levels

Submitted to ECOSOC on 28 February 2023

SDGs under Review

CND aim: Inclusion of a Reference the world drug problem and its multiple links to the 2030 Agenda in the SDG Summit Declaration

HLPF side event

SDG Summit 20-21 September 2023

CND Input

SDGs under Review

6. CLEANER WATER AND SANITATION
7. AFFORDABLE AND ACCESSIBLE MEDICINES
9. INDUSTRY, INNOVATION AND INFRASTRUCTURE
11. SUSTAINABLE CITIES AND COMMUNITIES
17. PARTNERSHIPS FOR THE GoalSD
➢ Continue to implement *coordinated multidisciplinary efforts* to ensure that *no one affected by the world drug problem is left behind* in the response to the COVID-19 pandemic

➢ *Accelerate the implementation* of all international drug policy commitments

➢ *Allocate sufficient funding and resources* for drug-related initiatives

➢ Strengthen measures, strategies and inter-agency and international *cooperation and partnerships* to ensure *access to and availability of controlled substances for medical and scientific purposes*

➢ *Take into consideration the links between drugs and the environment* in efforts to address the world drug problem

➢ *Mainstreaming an age and gender perspective* into all stages of the development, implementation, monitoring and evaluation of drug prevention, treatment, sustained recovery and related support services
Thank you!

http://cnd.unodc.org
@CND_tweets

www.unodc.org/2019MDFollow-Up
@ungass2016